Showing Form 4 filings for BBTX
Pre-configured institutional-grade criteria for instant high-conviction screening
Multiple insiders buying stock within the last 30 days
Direct open-market purchases by Chief Executive Officers
Financial chiefs and top corporate officers accumulating shares
Institutional-scale insider purchases of $1,000,000 or greater
Insiders increasing their overall equity ownership by over 20%
High-value executive divestments by CEOs and CFOs over $1M
Bambusa Therapeutics, Inc.
Price
$15.79
Shares
2,953,820
Ownership
1,495,971
Value/Share
Ra Capital Management, L.P.
Dir, 10%
Unknown
Industry